Experimental KRAS G12D Degrader Plus Chemotherapy Shrinks Tumors in 6 of 7 Assessed Pancreatic Cancer Patients
PT0253 plus modified FOLFIRINOX shrank tumors in six of seven assessable patients with newly treated metastatic pancreatic cancer, according to preliminary Phase 1 results without a comparison group.